SCHEMBL30793502

SCHEMBL30793502

CCNC(=O)c1nn2c(c1C)CN(C(=O)OC(C)(C)C)CCC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ NR1H2 P55055 1/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ PREP P48147 1/20 0.35
▸ PIK3CD O00329 1/20 0.35
▸ CYBB P04839 1/20 0.34
▸ NOX5 Q96PH1 1/20 0.34
▸ NOX4 Q9NPH5 1/20 0.34
▸ NOX1 Q9Y5S8 1/20 0.34
▸ CNR1 P21554 1/20 0.34
▸ CNR2 P34972 1/20 0.34
▸ NAMPT P43490 2/20 0.34
▸ MAPT P10636 1/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ PDE4A P27815 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ PDE4C Q08493 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30793120 0.88 GPR119 (0.37) GPR119KDM4EPKMNR1H2MEN1
SCHEMBL30793901 0.88 MEN1 (0.38) GPR119KDM4EPKMNR1H2MEN1
SCHEMBL25337124 0.88 KMT2A (0.36) KDM4EPKMNR1H2MEN1KMT2A
SCHEMBL30793753 0.87 MEN1 (0.37) NR1H2MEN1KMT2APREPCYBB
SCHEMBL25338426 0.84 NR1H2 (0.43) NR1H2MEN1KMT2APREPCYBB
SCHEMBL25336741 0.84 MEN1 (0.38) GPR119NR1H2MEN1KMT2APREP
SCHEMBL30793643 0.84 CNR1 (0.45) KDM4EMEN1KMT2ACNR1CNR2
SCHEMBL24535150 0.81 GPR119 (0.36) GPR119NR1H2MEN1KMT2APREP
SCHEMBL30793161 0.79 CDK5 (0.36) KDM4EPKMMEN1KMT2ACYBB
SCHEMBL31057453 0.78 GPR119 (0.37) GPR119NR1H2MEN1KMT2APREP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368649-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2025-12-04 — — US disclosed
EP-4540254-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
WO-2023244604-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368649-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS GPR119 2053/4885KDM4E 2625/4885PKM 4209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback